Clinical Policy: Bimekizumab (Bimzelx) — coverage criteria for dermatology and rheumatology indications
This policy governs medical necessity criteria, dosing limits, and prior authorization requirements for bimekizumab (Bimzelx) for Medicaid members for FDA‑approved indications (plaque psoriasis, psoriatic arthritis, axial spondyloarthritis/ankylosing spondylitis, non‑radiographic axial SpA, and hidradenitis suppurativa) and related continuation criteria.
Added newly approved indication for hidradenitis suppurativa (HS).
Added new 320 mg/2 mL strength for single-dose prefilled syringe and autoinjector.
Extended initial approval durations to 12 months for chronic conditions.
For PsO, AS, and HS, bypass of conventional therapies allowed if member previously failed a biologic agent.
For PsO and PsA, added requirement to use one preferred ustekinumab (Stelara) biosimilar prior to bimekizumab.
5FDA‑approved indications listed
320 mg/2 mLnew product strength added
12 months
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.
extended initial approval duration
≥18Minimum age requirement
YesDose limits specified
J3590/C9399Unclassified HCPCS referenced
Coverage and Medical Necessity Criteria
Initial Therapy — Plaque Psoriasis
Covered when ALL of the following are met:
Plaque Psoriasis initial criteria: 1. Diagnosis of moderate-to-severe plaque psoriasis as evidenced by ONE of: (a) ≥ 3% total body surface area OR (b) involvement of hands, feet, scalp, face, or genital area; 2. Prescribed by or in consultation with a dermatologist or rheumatologist; 3. Age ≥ 18 years; 4. One of the following prior conventional therapy trials, unless the member previously failed a biologic agent for PsO: (a) Failure of ≥ 3 consecutive month trial of methotrexate at up to maximally indicated doses; OR (b) Intolerance/contraindication to methotrexate and failure of ≥ 3 consecutive month trial of cyclosporine or acitretin at up to maximally indicated doses; OR (c) Intolerance/contraindication to methotrexate, cyclosporine, and acitretin and failure of phototherapy for ≥ 3 consecutive months (unless contraindicated or clinically significant adverse effects experienced); 5. ONE of the following biologic trials, unless contraindicated or clinically significant adverse effects: (a) Failure of ≥ 3 consecutive month trial of one adalimumab product; OR (b) History of failure of two TNF blockers; 6. Failure of ≥ 3 consecutive month trial of ixekizumab (Taltz), unless contraindicated or clinically significant adverse effects; 7. Failure of ≥ 3 consecutive month trial of one ustekinumab product, unless contraindicated or clinically significant adverse effects; 8. No combination use with other biologic DMARDs or Janus kinase inhibitors; 9. Dose does not exceed either: (a) 320 mg at weeks 0, 4, 8, 12, and 16 then every 8 weeks; OR (b) if weight ≥ 120 kg: 320 mg at weeks 0, 4, 8, 12, and 16 then every 4 weeks.age>=18;BSA>=3%
Prior authorization may be required for some comparator agents
Initial Therapy — Psoriatic Arthritis
Covered when ALL of the following are met:
PsA initial criteria: 1. Diagnosis of psoriatic arthritis; 2. Prescribed by or in consultation with a dermatologist or rheumatologist; 3. Age ≥ 18 years; 4. Failure of ALL of the following, each used for ≥ 3 consecutive months unless contraindicated or clinically significant adverse effects: (a) One adalimumab product (unless member has history of failure of two TNF blockers); (b) Otezla (apremilast); (c) Taltz (ixekizumab); (d) One ustekinumab product; (e) If member has not responded or is intolerant to one or more TNF blockers, trial of Xeljanz/Xeljanz XR unless cardiovascular risk outweighs benefit; 5. No combination use with other biologic DMARDs or Janus kinase inhibitors; 6. Dose does not exceed: (a) PsA alone: 160 mg every 4 weeks; OR (b) PsA with coexistent PsO: (i) 320 mg at weeks 0,4,8,12,16 then every 8 weeks; OR (ii) if weight ≥ 120 kg: 320 mg at weeks 0,4,8,12,16 then every 4 weeks.age>=18
Prior authorization may be required for multiple comparator agents
Initial Therapy — Axial Spondylitis
Covered when ALL of the following are met:
Axial spondylitis initial criteria: 1. Diagnosis of ankylosing spondylitis (AS) or non-radiographic axial spondyloarthritis (nr-axSpA); 2. Prescribed by or in consultation with a rheumatologist; 3. Age ≥ 18 years; 4. Failure of at least TWO NSAIDs at up to maximally indicated doses, each used for ≥ 4 weeks unless contraindicated, previously failed a biologic, or clinically significant adverse effects occurred; 5. For AS: failure of ALL of the following, each used > 3 consecutive months unless contraindicated or clinically significant adverse effects: (a) One adalimumab product (unless history of failure of two TNF blockers); (b) Taltz (ixekizumab); (c) If not responded/intolerant to one or more TNF blockers, Xeljanz/Xeljanz XR unless cardiovascular risk outweighs benefit; 6. For nr-axSpA: failure of Taltz for ≥ 3 consecutive months unless contraindicated or clinically significant adverse effects; 7. No combination use with other biologic DMARDs or Janus kinase inhibitors; 8. Dose does not exceed 160 mg every 4 weeks.age>=18
Approval duration: 12 months
Initial Therapy — Hidradenitis Suppurativa
Covered when ALL of the following are met:
HS initial criteria: 1. Diagnosis of hidradenitis suppurativa; 2. Prescribed by or in consultation with a dermatologist, rheumatologist, or gastroenterologist; 3. Age ≥ 18 years; 4. Documentation of Hurley stage II or III; 5. Failure of one adalimumab product unless the member has history of failure of two TNF blockers or adalimumab is contraindicated/intolerant; 6. Failure of at least TWO of the following, each tried ≥ 3 consecutive months from different therapeutic classes unless contraindicated or clinically significant adverse effects: (a) Systemic antibiotics (e.g., clindamycin, minocycline, doxycycline, rifampin); (b) Oral retinoids (e.g., acitretin, isotretinoin); (c) Hormonal treatment (e.g., estrogen-containing combined oral contraceptives, spironolactone); 7. No combination use with other biologic DMARDs or Janus kinase inhibitors; 8. Dose does not exceed 320 mg at weeks 0,2,4,6,8,10,12,14,16 then every 4 weeks.age>=18
Approval duration: 12 months
Continued Therapy
Covered when ALL of the following are met:
Continued therapy general criteria: 1. Member currently receiving medication via the benefit or previously met initial approval criteria, or member is receiving medication and enrolled in a state/product with continuity of care regulations; 2. Clinical response: For HS, at least 25% reduction in inflammatory nodules and abscesses; for other indications, member is responding positively to therapy; 3. No combination use with other biologic DMARDs or Janus kinase inhibitors; 4. If dose increase requested, new dose must not exceed indication-specific limits: (a) PsA, AS, nr-axSpA: 160 mg every 4 weeks; (b) PsO (with or without PsA): 320 mg every 8 weeks OR weight ≥ 120 kg: 320 mg every 4 weeks; (c) HS: 320 mg every 4 weeks.
Continuation approval length aligned with indication dosing limits
Indication-specific coverage criteria (summary)
Covered when dosing and indication align with FDA-labeled regimens and any policy-required prior biologic or preferred-product trials are met:
Psoriasis (PsO): Member has diagnosis of plaque psoriasis (with or without coexistent PsA) AND prescriber documents dosing per label: 320 mg SC at Weeks 0,4,8,12,16 then every 8 weeks (consider 320 mg every 4 weeks after Week 16 for patients ≥ 120 kg) AND required trials of preferred products (e.g., one preferred ustekinumab/Stelara biosimilar) have been attempted unless bypass criteria apply.
Bypass allowed if member failed a prior biologic; initial approvals extended to 12 months
Psoriatic Arthritis (PsA): Member has diagnosis of PsA AND prescriber documents dosing per label: 160 mg SC every 4 weeks AND required trials of preferred products have been attempted unless bypass criteria apply.
Bypass allowed if member failed a prior biologic; initial approvals extended to 12 months
Ankylosing Spondylitis (AS) & nr-axSpA: Member has diagnosis of AS or nr-axSpA AND prescriber documents dosing per label: 160 mg SC every 4 weeks AND required prior therapy trials per policy have been met or bypass applies.
Non‑FDA approved indications that are not specifically addressed in this policy are not authorized for coverage unless the provider supplies sufficient documentation of efficacy and safety consistent with the plan's off‑label use requirements (see policy CP.PMN.53 for Medicaid and other evidence‑of‑coverage guidance).
The listing or omission of billing or HCPCS codes in this policy is for informational purposes only. Inclusion or exclusion of a code does not by itself guarantee coverage; authorization and payment depend on meeting the applicable benefit, medical necessity criteria, and current coding guidance.
Requests for use of bimekizumab in combination with other immunosuppressive or biologic agents (including but not limited to TNF antagonists, interleukin agents, JAK inhibitors, anti‑CD20 antibodies, co‑stimulation modulators, integrin receptor antagonists, TYK2 inhibitors, and S1P modulators) are not authorized due to additive immunosuppression and the associated increased risk of neutropenia and serious infections.
Within the text extract provided there are no additional explicit "not medically necessary" statements beyond the combination‑use prohibitions and the non‑FDA indication exclusion referenced elsewhere; coding notes reiterate that code lists are informational and do not constitute authorization.
Coding and Dosing Details
Document header (no billing codes listed)mixed
No codes listed
HCPCS Codes (informational)HCPCS
J3590
Unclassified biologics
HCPCS Codes (informational)HCPCS
C9399
Unclassified drugs or biologicals
Body surface area — coverage threshold
BSA threshold≥ 3% of total body surface area
Alternate PsO involvementInvolvement of hands, feet, scalp, face, or genital area also meets criteria
Provider requirementPrescribed by or in consultation with a dermatologist or rheumatologist
Weight threshold for dosing adjustment
Weight threshold>= 120 kg — consider 320 mg every 4 weeks for psoriasis after Week 16
Standard PsO dosing (after loading)320 mg every 8 weeks (typical maintenance)
Provider Requirements, Prior Authorization, and Documentation
Prior Authorization
Provider Requirements, Prior Authorization, and Documentation
Prior authorization is required. Provider must document that the member has met all approval criteria, including required prior medication trials or exceptions noted in the specific indication criteria. Requests lacking required trial evidence, preferred biologic trial use (where applicable), or adequate clinical documentation may be denied.
Prior authorization required for bimekizumab (Bimzelx).
For PsO and PsA, member must have trialed one preferred ustekinumab (Stelara) biosimilar (Otulfi, Pyzchiva (branded), Selarsdi, Steqeyma, or Yesintek) prior to bimekizumab unless clinically contraindicated or member previously failed a biologic agent per April SDC update.
Step therapy: required trials of conventional systemic agents and comparators per indication (examples below — see indication-specific criteria): methotrexate (≥ 3 months), cyclosporine or acitretin (if MTX intolerant/contraindicated), phototherapy (where applicable), adalimumab product (≥ 3 months) or history of two TNF blocker failures, Taltz (ixekizumab) (≥ 3 months), ustekinumab product (≥ 3 months), Otezla (apremilast), Xeljanz (if applicable), and failure of two NSAIDs for axial spondylitis as specified.
Preferred biologic trial requirement applies to PsO and PsA per April SDC: trial/use of one preferred Stelara biosimilar is required prior to bimekizumab unless bypass criteria apply (e.g., prior biologic failure, contraindication, or intolerable adverse effects).
Required prior medication trials must be documented as used for the durations specified in the indication criteria (generally ≥ 3 consecutive months unless otherwise noted).
Background and Clinical Context
Bimekizumab (Bimzelx) is a humanized monoclonal antibody that antagonizes both interleukin‑17A and interleukin‑17F. It is indicated for adults with moderate‑to‑severe plaque psoriasis, psoriatic arthritis, ankylosing spondylitis and non‑radiographic axial spondyloarthritis, and for moderate‑to‑severe hidradenitis suppurativa. Dosing and administration follow labeled loading and maintenance regimens (for example, common regimens use 320 mg or 160 mg subcutaneous doses depending on indication and patient weight) and the policy requires that prescribers document indication, specialist involvement, and prior therapy trials or failures as specified for each indication.
Definitions and Abbreviations
Body surface area (BSA) definition/threshold references
Hidradenitis Suppurativa (HS): Member has diagnosis of moderate-to-severe HS (Hurley stage II or III) AND prescriber documents dosing per label: 320 mg SC at Weeks 0,2,4,6,8,10,12,14,16 then every 4 weeks AND prior trial of a preferred adalimumab product has been attempted unless contraindicated or clinically significant adverse effects occurred (bypass allowed).
Newly approved indication; initial approvals extended to 12 months
Loading regimen reference320 mg at Weeks 0,4,8,12,16 before maintenance
Dose and indication must be documented and consistent with labeled regimens (see Dosage and Administration): PsO loading and maintenance schedules, PsA 160 mg every 4 weeks, AS/nr-axSpA 160 mg every 4 weeks, HS loading series then 320 mg every 4 weeks, and weight-based adjustments for patients ≥ 120 kg where specified.
Provider must submit supporting clinical documentation: office chart notes, laboratory results, imaging, prior therapy dates/dosing and reason for discontinuation (e.g., lack of efficacy or adverse effects), specialist consultation notes when required (dermatologist or rheumatologist), and any documentation supporting contraindications to preferred agents.
Combination therapy exclusion: requests for combination use with other biologic DMARDs, potent immunosuppressants, JAK inhibitors, anti-CD20 antibodies, and the agents listed in Section III are not authorized and should be documented if attempted.
Coding does not guarantee coverage: inclusion or exclusion of codes (e.g., HCPCS J3590, C9399) in this policy is informational only and does not authorize payment. Providers must follow current professional coding guidance when submitting claims.
Prescriber requirement
Prescribed by or in consultation with a dermatologist or rheumatologist; age ≥ 18 years
Psoriatic arthritis (PsA) definition
TermPsoriatic arthritis (PsA)
Coverage definitionDiagnosis of PsA with prescriber documentation; age ≥ 18 years; dosing per label (160 mg every 4 weeks)
Therapy trialsPolicy requires specified prior trials/failures of biologics and other agents per indication before approval unless bypass applies
Ankylosing spondylitis (AS) definition
TermAnkylosing spondylitis (AS)
Coverage definitionDiagnosis of AS or nonradiographic axial spondyloarthritis (nr-axSpA); prescribed by/with rheumatologist; age ≥ 18 years
Dose limitMaintenance dosing does not exceed 160 mg every 4 weeks
Hidradenitis suppurativa (HS) definition
TermHidradenitis suppurativa (HS)
Coverage definitionModerate-to-severe HS (Hurley stage II or III) with prescriber documentation; age ≥ 18 years
Prior therapy requirementFailure of one adalimumab product plus failure of at least two systemic therapies from different classes (each ≥3 months) unless contraindicated
Hurley staging for HS — stage descriptions and relevance to coverage
Hurley stage IIModerate HS: recurrent abscesses with sinus tracts and scarring; single or multiple widely separated lesions
Hurley stage IIISevere HS: diffuse or near-diffuse involvement with multiple interconnected tracts and abscesses across an area
Relevance to coveragePolicy requires documentation of Hurley stage II or III for HS coverage of bimekizumab
Failure of MTX/DMARDs — general note and how failure is defined
General definition of failureFailure of MTX or DMARDs is defined in Appendix D of the policy (see Appendix D for specifics)
MTX specificsChildbearing age and social alcohol use alone are not absolute contraindications to MTX; definitions of contraindication and failure are in Appendix D
Operational requirementPolicy requires a ≥ 3 consecutive month trial of methotrexate at up to maximally indicated doses to constitute failure for PsO unless previously failed a biologic—this trial requirement is part of initial-therapy criteria